|
The Indian Pharmacopoeia Commission (IPC), which is the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (NCC-PvPI), is set to host the 36th Skill Development Programme (SDP) on Pharmacovigilance (PV) scheduled from 9 to 13th March, 2026 through online mode.
IPC is also the WHO Collaborating Centre for Pharmacovigilance (PV) in Public Health Programmes and Regulatory Services.
PV plays a critical role in ensuring drug safety and efficacy, monitoring the adverse effects of pharmaceutical products, and promoting patient safety. It involves the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary goal of PV is to enhance patient care and safety in relation to the use of medicines, ensuring that the benefits of drugs outweigh the risks.
Eligibility for SDP are students of pharmacy, Pharm D, MBBS/BDS, and nursing, young professionals in PV, pharmacists, nurses, doctors, academicians, industry professionals, consumers and NGOs.
The SDP aims to provide comprehensive training on PV principles, including ADR reporting and risk management, develop practical skills required for effective PV practices, foster an understanding of global and national PV standards and regulatory requirements, facilitate networking and collaboration among healthcare professionals, regulatory authorities, and industry stakeholders.
This SDP represents a valuable opportunity for students, healthcare professionals, and stakeholders in the PV sector to advance their knowledge and skills. By participating, individuals will contribute to the overarching goal of ensuring drug safety and promoting public health in India. The IPC remains committed to fostering an environment of learning and collaboration, pivotal to achieving excellence in PV practices.
IPC is an autonomous institution of the Union ministry of health and family welfare created to set standards of drugs in the country. Its basic function is to regularly update the standards of drugs commonly required for treatment of diseases prevailing in this region. It publishes official documents for improving quality of medicines by way of adding new and updating existing monographs in the form of Indian Pharmacopoeia (IP). It further promotes rational use of generic medicines by publishing National Formulary of India (NFI).
IP prescribes standards for identity, purity and strength of drugs essentially required from the health care perspective of human beings and animals. IPC also provides IP Reference Substances (IPRS) which act as a fingerprint for identification of an article under test and its purity as prescribed in IP.
|